Turnaround For Spectrum’s Poziotinib As Phase II Cohort 2 Meets Endpoint

 
• By Jung Won Shin
  
Digital illustration of Cancer cell in colour background
Spectrum To Discuss Poziotinib With FDA To Determine Path Forward • Source: Shutterstock

More from South Korea

More from Focus On Asia